tions have been noted to be beneficial, as reported in retrospective case series, no rigorous, prospective studies have been completed in this population. In regard to the question above, there is no evidence (level I, II, III or IV) to support or reject evaluation of the skin or gut microbiome after neoadjuvant or adjuvant chemotherapy.

Conceptually, chemotherapy is known to alter the gut microbiome, which likely influences the development and manifestations of chemotherapy-associated mucositis [8–10]. When undergoing induction chemotherapy for acute myeloid leukemia, patients who developed infection after treatment were shown to have significantly lower baseline stool bacteria diversity and the therapy itself was shown to decrease microbiome diversity [11]. Taxonomic shifts in the gut biome have been demonstrated in lymphoma patients following chemotherapy, with decreases in Firmicutes (species including *Staphylococcus, Streptococcus, Enterococcus*) and Actinobacteria (*Streptomyces, Proprionibacteria*) and increases in Proteobacteria (*Escherichia, Salmonella, Vibrio, Helicobacter, Yersinia, Legionellales*) [8]. In a pediatric study of acute lymphoblastic leukemia (ALL), the abundance of Proteobacteria in the gut microbiome before chemotherapy was predictive of the infection risk and domination of the gut by *Enterococcaceae* or *Streptococcaceae* during current and subsequent phases of chemotherapy [12]. Decreased diversity in the taxa of the gut microbiome has been used as a predictive tool for chemotherapy-related bloodstream infection risk [13]. Chemotherapy alters the skin microbiome in that fungal infections are common during and following chemotherapy [14].

Despite these documented changes in the microbiome of the gut and on the skin and their relation to infection risk, there is no proven association or theoretical link with postoperative endoprosthetic infection. This is illustrated in two ways. First, the causative organisms of endoprosthetic infection are those typically found in postoperative periprosthetic joint infections (e.g., *Staphylococcus, Streptrococcus, Enterococcus,* Pseudomonas species) [2,7,15], which are not species noted to increase following chemotherapy (e.g., *Proteobacteria* and Fungi) [8]. Second, the average time to infection-related surgical revision of endoprostheses is 47 months following index endoprosthesis placement [1]. This timeline is long after chemotherapy has been completed and more than enough time for chemotherapy-induced changes in the diversity of the gut and skin microbiome to return to normal.

There is still a need for further research to clarify whether skin and gut microbiome testing would prove useful in risk stratification for infection following endoprosthetic reconstruction.

REFERENCES

[1]   Henderson ER, et al. Failure mode classification for tumor endoprostheses: retrospective review of five institutions and a literature review. J Bone Joint Surg Am. 2011. 93(5):418–429.

[2]   Morii T, Yabe H, Morioka H, Beppu Y, Chuman H, Kawai A, et al. Postoperative deep infection in tumor endoprosthesis reconstruction around the knee. J Orthop Sci. 2010;15:331–339. doi:10.1007/s00776-010-1467-z.

[3]   Nobile M, Navone P, Domeniconi G, Della Valle A, Daolio PA, Buccino NA, et al. Surgical site infections in oncologic orthopaedic prosthetics surgery. Ann Ig. 2015;27:711–717.

[4]   Haijie L, Dasen L, Tao J, Yi Y, Xiaodong T, Wei G. Review: implant survival and complication profiles of endoprostheses for treating tumor around the knee in adults: a systematic review of the literature over the past 30 years. J Arthroplasty. 2018;33:1275–1287.e3. doi:10.1016/j.arth.2017.10.051.

[5]   Kapoor SK, Thiyam R. Management of infection following reconstruction in bone tumors. J Clin Orthop Trauma. 2015;6:244–251. doi:10.1016/j.jcot.2015.04.005.

[6]   Pugh LR, Clarkson PW, Phillips AE, Biau DJ, Masri BA. Tumor endoprosthesis revision rates increase with peri-operative chemotherapy but are reduced with the use of cemented implant fixation. JArthroplasty. 2014;29:1418–1422. doi:10.1016/j.arth.2014.01.010.

[7]   Morii T, Morioka H, Ueda T, Araki N, Hashimoto N, Kawai A, et al. Deep infection in tumor endoprosthesis around the knee: a multi-institutional study by the Japanese musculoskeletal oncology group. BMC Musculoskel Disord. 2013;14:51. doi:10.1186/1471-2474-14-51.

[8]   Montassier E, et al. Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther. 2015. 42(5):515–528.

[9]   Bai J, Behera M, and Bruner DW. The gut microbiome, symptoms, and targeted interventions in children with cancer: a systematic review. Support Care Cancer. 2018;26(2):427–439.

[10] Nycz BT, et al. Evaluation of bloodstream infections, Clostridium difficile infections, and gut microbiota in pediatric oncology patients. PLoS One. 2018;13(1):e0191232.

[11] Galloway-Peña JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, et al. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia: microbiome analyses of patients with AML. Cancer. 2016;122:2186–2196. doi:10.1002/cncr.30039.

[12] Hakim H, Dallas R, Wolf J, Tang L, Schultz-Cherry S, Darling V, et al. Gut microbiome composition predicts infection risk during chemotherapy in children with acute lymphoblastic leukemia. Clin Infect Dis. 2018. doi:10.1093/cid/ciy153.

[13] Montassier E, Al-Ghalith GA, Ward T, Corvec S, Gastinne T, Potel G, et al. Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection. Genome Med. 2016;8. doi:10.1186/s13073-016-0301-4.

[14] Teoh F, and Pavelka N. How chemotherapy increases the risk of systemic Candidiasis in cancer patients: current paradigm and future directions. Pathogens. 2016;5(1):pii:e6.

[15] Hardes J, Henrichs M-P, Gosheger G, Guder W, Nottrott M, Andreou D, et al. Tumour endoprosthesis replacement in the proximal tibia after intra-articular knee resection in patients with sarcoma and recurrent giant cell tumour. Int Orthop. 2018. doi:10.1007/s00264-018-3893-z.

● ● ● ● ●

Authors: Andreas F. Mavrogenis, Takeshi Morii, Jorge Manrique

QUESTION 2: Should an absolute neutrophil count of > 1000/mm³ be the minimum for patients undergoing limb salvage surgery after receiving chemotherapy?

RECOMMENDATION: Yes. An absolute neutrophil count of >1000/mm³ should be the minimum for patients undergoing limb salvage surgery after receiving chemotherapy.

LEVEL OF EVIDENCE: Consensus

DELEGATE VOTE: Agree: 100%, Disagree: 0%, Abstain: 0% (Unanimous, Strongest Consensus)

RATIONALE

Neutropenia has been defined as an absolute neutrophil count (ANC) of 1500/mm³ or lower [1]. Historically, this cutoff value has been considered as a risk factor for developing infections and complications. Bodey et al. [2] initially described this association.

They observed that the infection rate in patients with ANC below 1000/mm³ was 14% and below 100/mm³ up to 60% [2]. Furthermore, lower ANC levels have been identified as an independent risk factor for infections [3]. This latter publication also demonstrated that the

risk gradually increases as ANC decreases. In a more recent study, Lima et al. [4] evaluated patients with ANC levels less than or equal to 500 cells/mm³ further support this relationship.

Different chemotherapeutic agents are used in the treatment of bone and soft tissue sarcomas. Some have shown to be myelosuppressive and thus reduce the ANC [5]. This is also one of the most critical criteria to administering chemotherapeutic regimens as it has been directly associated with an increased risk of complications [3,6]. The combination of wide resection and neo-adjuvant/adjuvant chemotherapy is a standard treatment modality for bone sarcomas [7]. The combination of methotrexate (MTX), doxorubicin (ADR), cisplatin (CDDP) and ifosfamide (I) are agents used for conventional osteosarcoma [7–11]. For small round cell sarcoma including Ewing's sarcoma, multi-agent chemotherapy with vincristine-doxorubicin-cyclophosphamide, ifosfamide-etoposide (VDC-IE) is used [12,13]. Chemotherapy for high-grade non-round cell, soft tissue sarcoma is controversial, but the effectiveness of chemotherapy for such sarcomas has been shown in several studies [14–20]. The conventional key drugs for such condition include ADR and I [14,15,17]. In addition, dacarbazine (DTIC), gemcitabine (G) and docetaxel (D) became the options for soft tissue sarcomas [20–24]. Recent innovation in this area provided additional reagents including pazopanib, trabectedin and eribulin, which are mainly used as second line treatment for advanced soft tissue sarcomas [25–31].

When evaluating patients with low ANC undergoing surgical interventions, these patients also exhibit an increased risk of surgical site infection compared to patients with normal counts. Natour et al. [32] evaluated patients undergoing abdominal surgery in the setting of neutropenia. They categorized patients with ANC < 500/mm³, between 500/mm³ and 1000/mm³, and between 1000/mm³ and 1500/mm³. Patients with lower ANC also exhibited higher postoperative infection rates, hospital stay and mortality. A relatively recent study evaluated the risk for infection of implantable port devices in pediatric oncology patients [33]. Again, patients with low ANCs had higher infection rates compared to those with normal ANC.

No study was identified that directly associates infection risk in patients undergoing limb salvage and low ANC. Given that limb salvage surgery is a complex procedure, all efforts to avoid infection should be undertaken. Based on the available literature, we consider that patients with an ANC below 1000/mm³, either from the chemotherapy or the solid tumor itself, should not undergo limb salvage surgery until ANC is above 1000/mm³ and possibly above 1500/mm³.

REFERENCES

[1]   Newburger PE, Dale DC. Evaluation and management of patients with isolated neutropenia. Semin Hematol. 2013;50:198–206. doi:10.1053/j.seminhematol.2013.06.010.

[2]   Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328–340.

[3]   Rosenfeld SI. Neutropenia: an analysis of the risk factors for infection. Yale Med Thesis Digit Libr. 1980;3087.

[4]   Lima SS, França MS, Godoi CC, Martinho GH, de Jesus LA, Romanelli RM, et al. Neutropenic patients and their infectious complications at a University Hospital. Rev Bras Hematol Hemoter. 2013;35:18–22. doi:10.5581/1516-8484.20130009.

[5]   Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C, et al. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol. 1992;10:1266–1277. doi:10.1200/JCO.1992.10.8.1266.

[6]   Boxer L, Dale DC. Neutropenia: causes and consequences. Semin Hematol. 2002;39:75–81.

[7]   Biermann JS, Chow W, Reed DR, Lucas D, Adkins DR, Agulnik M, et al. NCCN Guidelines Insights: bone cancer, Version 2.2017. J Natl Compr Canc Netw. 2017;15:155–167.

[8]   Iwamoto Y, Tanaka K, Isu K, Kawai A, Tatezaki S, Ishii T, et al. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci. 2009;14:397–404. doi:10.1007/s00776-009-1347-6.

[9]   Iwamoto Y, Tanaka K. The activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 2012;42:467–470. doi:10.1093/jjco/hys059.

[10] Ferrari S, Ruggieri P, Cefalo G, Tamburini A, Capanna R, Fagioli F, et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol. 2012;30:2112–2118. doi:10.1200/JCO.2011.38.4420.

[11] Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17:1396–1408. doi:10.1016/S1470-2045(16)30214-5.

[12] Fox E, Widemann BC, Hawkins DS, Jayaprakash N, Dagher R, Aikin AA, et al. Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. Clin Cancer Res. 2009;15:7361–7367. doi:10.1158/1078-0432.CCR-09-0761.

[13] Spunt SL, Irving H, Frost J, Sender L, Guo M, Yang B-B, et al. Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients. J Clin Oncol. 2010;28:1329–1336. doi:10.1200/JCO.2009.24.8872.

[14] Nielsen OS, Judson I, van Hoesel Q, le Cesne A, Keizer HJ, Blay JY, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2000;36:61–67.

[15] Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13:1045–1054. doi:10.1016/S1470-2045(12)70346-7.

[16] Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012;30:850–856. doi:10.1200/JCO.2011.37.7218.

[17] Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay J-Y, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15:415–423. doi:10.1016/S1470-2045(14)70063-4.

[18] Tanaka K, Mizusawa J, Fukuda H, Araki N, Chuman H, Takahashi M, et al. Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304). Jpn J Clin Oncol. 2015;45:555–561. doi:10.1093/jjco/hyv042.

[19] von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Conrad EU, et al. Soft tissue sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14:758–786.

[20] Bui-Nguyen B, Ray-Coquard I, Chevreau C, Penel N, Bay JO, Coindre JM, et al. High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. Ann Oncol. 2012;23:777–784. doi:10.1093/annonc/mdr282.

[21] Kataoka K, Tanaka K, Mizusawa J, Kimura A, Hiraga H, Kawai A, et al. A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306. Jpn J Clin Oncol. 2014;44:765–769. doi:10.1093/jjco/hyu080.

[22] Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1397–1410. doi:10.1016/S1470-2045(17)30622-8.

[23] García-Del-Muro X, López-Pousa A, Maurel J, Martín J, Martínez-Trufero J, Casado A, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011;29:2528–2533. doi:10.1200/JCO.2010.33.6107.

[24] Lee EM, Rha SY, Lee J, Park KH, Ahn J-H. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. Cancer Chemother Pharmacol. 2012;69:635–642. doi:10.1007/s00280-011-1742-5.

[25] van der Graaf WTA, Blay J-Y, Chawla SP, Kim D-W, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879–1886. doi:10.1016/S0140-6736(12)60651-5.

[26] Baruchel S, Pappo A, Krailo M, Baker KS, Wu B, Villaluna D, et al. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. Eur J Cancer. 2012;48:579–585. doi:10.1016/j.ejca.2011.09.027.

[27] Ueda T, Kakunaga S, Ando M, Yonemori K, Sugiura H, Yamada K, et al. Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma. Invest New Drugs. 2014;32:691–699. doi:10.1007/s10637-014-0094-5.

[28] Le Cesne A, Blay J-Y, Domont J, Tresch-Bruneel E, Chevreau C, Bertucci F, et al. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. Lancet Oncol. 2015;16:312–319. doi:10.1016/S1470-2045(15)70031-8.

[29] Kawai A, Araki N, Sugiura H, Ueda T, Yonemoto T, Takahashi M, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol. 2015;16:406–416. doi:10.1016/S1470-2045(15)70098-7.

[30] Kawai A, Araki N, Naito Y, Ozaki T, Sugiura H, Yazawa Y, et al. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. Jpn J Clin Oncol. 2017;47:137–144. doi:10.1093/jjco/hyw175.

[31] Schöffski P, Ray-Coquard IL, Cioffi A, Bui N Bin, Bauer S, Hartmann JT, et al.

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011;12:1045–1052. doi:10.1016/S1470-2045(11)70230-3.

[32] Natour RHA, Ashley SW, Tavakkolizadeh A. 797 outcomes of abdominal surgery in neutropenic patients. Gastroenterol. 2010;138:S-860. doi:10.1016/S0016-5085(10)63966-2

[33] Dogar SA, Khan MAM. Implantable port devices in paediatric oncology patients: a clinical experience from a tertiary care hospital. J Pak Med Assoc. 2013;63:1248–1251.

● ● ● ● ●

Authors: Michiel van de Sande, Hiroyuki Tsuchiya, Diasuke Inoue, John Strony

QUESTION 3: Should the serum white blood cell (WBC) count be taken into account prior to endoprosthetic reconstruction in patients who have undergone recent chemotherapy?

RECOMMENDATION: The association between chemotherapy and infection following endoprosthetic reconstruction remains controversial. However, in a multifactorial decision making process, there may be some benefit in accounting for the serum WBC count prior to endoprosthetic reconstruction.

LEVEL OF EVIDENCE: Limited

DELEGATE VOTE: Agree: 100%, Disagree: 0%, Abstain: 0% (Unanimous, Strongest Consensus)

RATIONALE

Infection continues to be one of the most serious complications after the reconstruction of an extremity using a tumor endoprosthesis. Past reports showed that the infection rate of a tumor endoprosthesis ranged from 4–36% [1–5]. The myelosuppressive properties of many chemotherapeutic drugs remain a theoretical risk for developing infection in these patients receiving a tumor endoprosthesis for an extremity tumor or metastatic lesions. However, this theoretical risk remains controversial. A handful of studies demonstrate a significant relationship between chemotherapy and periprosthetic infection in patients receiving an endoprosthetic device for an extremity tumor [3,6–9].

On the contrary, there are numerous studies that provide data supporting the idea that chemotherapy is not a significant risk factor for the development of periprosthetic joint infection (PJI) and surgical site infection (SSI) in these patients. Peel et al. [10] were able to demonstrate that chemotherapy, febrile neutropenia and bacteremia were not associated with the development of PJI. Jeys et al. [11] showed that there was no significant relationship between chemotherapy and the risk of infection. Biau et al. [12] reported that there was no significant difference in the rate of infection between patients who had received adjuvant treatment (including irradiation and chemotherapy) and those who had not received such treatment (p = 0.13). Finally, Meijer et al. [13] found no association between chemoradiation and increased rates of endoprosthetic infection.

Despite the conflicting evidence surrounding chemotherapy and the risk of endoprosthetic infection, there may be some benefit in taking into account the patient's serum WBC count prior to endoprosthetic reconstruction. It is widely known that lymphocytes play an essential role in combatting invading pathogens and facilitating wound healing after surgery [14]. In addition, Gulack et al. [15] reported that preoperative leukopenia prior to emergent abdominal surgery was a predictor for significant postoperative morbidity and mortality. However, they were not able to demonstrate a significant difference in the incidence of deep wound infection in patients with leukopenia vs. patients with a normal WBC count preoperatively (p = 0.462). These findings contrast with the work by Natour et al. [16], who noted that patients undergoing abdominal surgery with a preoperative absolute neutrophil count (ANC) less than 500

had significantly higher postoperative infection rates compared to patients who had a preoperative ANC between 500 and 1500. However, one must be cautious with the results from these studies, as they may not be generalizable to the particular patient cohort of focus.

Due to the fact that the literature doesn't show any significant differences between the infection rates between patients who are undergoing chemotherapy and those who are not receiving it, it makes sense to determine the WBC number as an additional diagnostic tool.

REFERENCES

[1] Hardes J, Gebert C, Schwappach A, Ahrens H, Streitburger A, Winkelmann W, et al. Characteristics and outcome of infections associated with tumor endoprostheses. Arch Orthop Trauma Surg. 2006;126:289–296. doi:10.1007/s00402-005-0009-1.

[2] Zajonz D, Wuthe L, Tiepolt S, Brandmeier P, Prietzel T, von Salis-Soglio GF, et al. Diagnostic work-up strategy for periprosthetic joint infections after total hip and knee arthroplasty: a 12-year experience on 320 consecutive cases. Patient Saf Surg. 2015;9:20. doi:10.1186/s13037-015-0071-8.

[3] Pala E, Trovarelli G, Calabrò T, Angelini A, Abati CN, Ruggieri P. Survival of modern knee tumor megaprostheses: failures, functional results, and a comparative statistical analysis. Clin Orthop Relat Res. 2015;473:891–899. doi:10.1007/s11999-014-3699-2.

[4] Sevelda F, Schuh R, Hofstaetter JG, Schinhan M, Windhager R, Funovics PT. Total femur replacement after tumor resection: limb salvage usually achieved but complications and failures are common. Clin Orthop Relat Res. 2015;473:2079–2087. doi:10.1007/s11999-015-4282-1.

[5] Haijie L, Dasen L, Tao J, Yi Y, Xiaodong T, Wei G. Implant survival and complication profiles of endoprostheses for treating tumor around the knee in adults: a systematic review of the literature over the past 30 years. J Arthroplasty. 2018;33:1275-1287.e3. doi:10.1016/j.arth.2017.10.051.

[6] Gaur AH, Liu T, Knapp KM, Daw NC, Rao BN, Neel MD, et al. Infections in children and young adults with bone malignancies undergoing limb-sparing surgery. Cancer. 2005;104:602–610. doi:10.1002/cncr.21212.

[7] Schinhan M, Tiefenboeck T, Funovics P, Sevelda F, Kotz R, Windhager R. Extendible prostheses for children after resection of primary malignant bone tumor: twenty-seven years of experience. J Bone Joint Surg Am. 2015;97:1585–1591. doi:10.2106/JBJS.N.00892.

[8] Ji T, Guo W, Yang RL, Tang XD, Wang YF. Modular hemipelvic endoprosthesis reconstruction–experience in 100 patients with mid-term follow-up results. Eur J Surg Oncol. 2013;39:53–60. doi:10.1016/j.ejso.2012.10.002.

[9] Guo W, Ji T, Yang R, Tang X, Yang Y. Endoprosthetic replacement for primary tumours around the knee: experience from Peking University. J Bone Joint Surg Br. 2008;90:1084–1089. doi:10.1302/0301-620X.90B8.20240.

[10] Peel T, May D, Buising K, Thursky K, Slavin M, Choong P. Infective complications following tumour endoprosthesis surgery for bone and soft tissue tumours. Eur J Surg Oncol. 2014;40:1087–1094. doi:10.1016/j.ejso.2014.02.241.